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Abstract: Introduction: Heart valve tissue engineering has been presented as a “promising” solution” for over 20 years. 
These living devices are supposed to have the capacity to grow, heal and repair or remodel. This would avoid structural 
valve degeneration of currently used biological heart valve prostheses or the need for life-long anticoagulation or 
mechanical devices. Especially for patients with stenotic aortic valve disease, which is the third most common 
cardiovascular condition in Western societies, this solution might be useful.  
Methods: A literature search has been performed for the years 2010-2014 with focus for results of tissue engineered 
valves of in-vitro, in-vivo animal and patient studies  
Results: Most experiments were still in-vitro. Especially those experiments which focus on synthetic biodegradable 
scaffolds have not left the laboratory, because these cannot withstand systemic pressures. The animal studies involved 
scaffolds of biologic origin with or without reseeding with cells. Cells were harvested from vascular, embryonal tissues or 
from bone marrow. Large animal studies (ovine, porcine) dealt with implantations in pulmonary position and right 
ventricular reconstruction, which might be useful in the treatment of congenital heart defects. Implantation in the 
systemic – high pressure – circulation were only performed in small animals (rat model). One goat model showed some 
remarkable results, but only on very short time.  
Conclusions: Tissue engineered valves seemed very promising, a promise that will not be fulfilled soon. Synthetic 
bioresorbable scaffolds have not left the laboratory yet. Scaffolds of biologic origin already have been tested in animals, 
mostly in pulmonary origin. It is by no means certain that behavior of tissue engineered valves in animals reflect the 
clinical situation, which is much more demanding. Also non-scientific hurdles such as official registration and 
commercialization of such devices have to be taken.  
Keywords: Cell source, Scaffold, Bioreactor, In vivo, In vitro, Aortic valve disease.  
INTRODUCTION 
Calcified aortic valve stenosis, is the most common 
valve disease in Western societies. Replacement of the 
diseased valve is the only option to prolong life and 
alleviate invalidating symptoms. This replacement is 
possible by mechanical and biological valves. 
Mechanical are very durable but require life-long 
anticoagulation. Porcine or bovine pericardial biological 
valves are more suitable for elderly patients, since 
immunity and hence inflammation decreases with age. 
This results in an increased durability in this age group. 
Especially in the difficult age group of 55 – 70 years, 
there is a trade-off between life-long anticoagulation 
with its inherent risk for bleeding and the risk for 
structural valve degeneration, with need for reoperation 
[1]. Our own results with pericardial valves in elderly 
patients were favourable [2-4]. The pericardial valve is 
very durable and approaches that of the homograft, 
which can be considered as the gold standard [5]. 
However, the availability of homograft devices is a 
problem. In order to avoid the necessity of life-long 
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anticoagulation or the risk for structural valve 
degeneration, tissue engineered valves (TEHV), have 
been proposed as a solution. These devices are 
considered as living structures, capable of growth, 
remodelling and in-vivo repair. This is not possible with 
current mechanical or biological devices. TEHV could 
also be helpful in repairing congenital heart defects. 
This however is beyond the scope of this manuscript. 
There are several approaches in use to construct 
TEHV [6]: 1) cell seeding on biodegradable scaffold 
with subsequent maturing in a bioreactor; 2) cell 
seeding on natural biodegradable scaffold; 3) guided 
tissue regeneration / remodelling of implanted 
degradable tissues by cells of the host, and 4) 
implantation of decellularized devices. The question 
remains: what research has been done so far in vitro, 
in animal studies and what are the results in patients.  
METHODS 
A systematic review of literature was performed by 
searching of electronic database “ISI web of 
knowledge”. The time span was from 2010 to 2014 and 
the used search terms were “tissue engineered heart 
valve AND animal” (48 items), “tissue engineered heart 
valve AND ovine” (26 items), and “tissue engineered 
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heart valve AND patient* (71 items). Forty-one multiple 
references were identified. Irrelevant papers (not 
dealing with cardiac tissue engineering), conference 
proceedings, book series and reviews were also 
removed (n=47). A search in the references of the 
identified articles did not result in more useful 
manuscripts. The papers were divided in pure “in vitro” 
and “in vivo” results”. Any research papers in which 
living animals were involved were classified as “in 
vivo”.  
RESULTS 
The search resulted in 29 full articles. There were 
18 papers dealing with “in vitro” experiments. Table 1 
summarizes the main data concerning cells and 
matrices which are used [7-20]. The main cell sources 
include valvar interstitial cells, fibroblasts, endothelial 
cells, smooth muscle cells and mesenchymal or bone 
marrow stem cells. The matrices most in use are 
biodegradable polymers such as polyglycolic acid, 
polyhydroxyalkanoate or poly-4-hydroxybutyrate, or a 
combination, which are tested for their biomechanical 
properties. Electrospinning has become a modern 
mode of fabrication of such synthetic bioresorbable 
scaffolds [8, 12].  
Some papers deal with specific issues, which are 
not included in the table. Two manuscripts deal with a 
first issue, namely biocompatibility and immunological 
considerations such as absence of Gal-epitopes in 
decellularized pulmonary root conduits, in which the 
extracellular matrix was partially preserved. This could 
make such devices potentially suitable as substitute for 
the right ventricular outflow tract in the Ross procedure 
[21, 22]. A second issue deals with the interspecies 
comparison of biomechanical properties. Ovine and 
porcine valves are much more compliant compared to 
aged human valves. The latter contain more collagen 
and elastin compared to ovine valves. Therefore, 
animal models do not necessarily represent 
biomechanical properties present in elderly patients, 
which are most in need for valve replacement [23]. The 
last issue concerns the development of pulse reactors, 
hemodynamic and imaging systems [24], which is not 
the focus of this review.  
Ten papers can be qualified as “in vivo” since an 
implantation in animals was involved. The main data 
are summarized in Table 2 [25-33]. Most of these 
articles involve implantation, of devices in pulmonary 
position. Two articles deal with implantation of a U-
shaped decellularized device implanted at the level of 
the infra-renal aorta of a rat. The aorta was ligated and 
the device which serves as bypass was sutured end-to-
side on the aorta. Another remarkable goat model 
showed that two months after implantation of a mould 
in dorsal subcutaneous tissue, a semilunar valve like 
Table 1:  In Vitro Studies  
Reference Cell Source Scaffold Type Mode of Analysis  
7 VIC and MSC biodegradable tri-layered biomechanical  
8 human VIC biodegradable* biomechanical, IHC 
9 human fibroblasts stented tissues biomechanical  
10 none  acellular porcine IHC pulmonary root 
11 ovine umbilical vein fibrin derived textile reinforced IHC 
12 ovine mitral VIC biodegradable* hyaluron hydrogrel biochemical 
13 periodontal lig. cells fibrin-derived  biochemical 
14  VIC composite biodegradable biochemical & biomechanical 
15 non-contractile cells fibrin-derived  biomechanical & biochemical 
16 Aortic VIC & SMC collagen gel & osteogenic medium mRNA expression, IHC 
17 Ovine myofibroblasts human VSM cells biodegradable  biomechanical  
18 fetal amniotic umbilical blood cells biodegradable  Biomechanical biochemical, HIS, SEM 
19 CD133 positive human bone marrow cells 
fibrin-derived & decellularized porcine 
pulmonary valve biomechanical, IHC 
20 MSC Decellularized porcine pericardium + PA IHC 
IHC: immunohistochemistry; lig. ligament; PA: pulmonary artery SEM: scanning electron microscope; SMC: smooth muscle cells; VIC: valve interstitial cells; VSM: 
vena saphena magna; * by electrospinning  
8 International Journal of Cardiology and Lipidology Research, 2016, Vol. 3, No. 1 Wilhelm P. Mistiaen 
construct of connective tissue of type VI can be formed. 
This proved to be of adequate strength and elasticity. 
Sufficient opening and coaptation of the leaflets could 
be demonstrated in vitro. The device was implanted as 
an apical-aortic bypass, which was monitored 
hemodynamically for 2 months. After explantation, the 
valves still looked as native aortic valves. Collagen, 
some elastin, fibroblast and smooth muscle cells could 
be demonstrated. There was no lining of endothelial 
cells. Thrombus formation was absent, however [28]. 
No series involving patients could be identified in the 
current search. 
DISCUSSION 
The search for the ideal tissue engineered heart 
valve is still ongoing. Dozens of scientific manuscripts 
are produced annually. A considerable part of these 
papers are reviews. This paper attempts to give a short 
overview of what has been performed in the last 5 
years, from 2010 to 2014. It is immediately clear that 
most research manuscripts are devoted to in-vitro 
testing of constructs. There is a wide variation in 
scaffolds (synthetic and biologic), in cells (vascular, 
bone marrow and foetal) and in culture media. The 
majority of in-vivo experiments is focused on devices 
implanted in pulmonary position. This is useful in 
paediatric patients with congenital heart defects, but 
this is a rather small population, with complex and 
variable pathology. Devices with artificial scaffolds lack 
stability, which can result in early failure, especially in 
high pressure systems. For patients with left sided 
heart valve disease, of which aortic valve stenosis is 
the most common, experiments with implants in the 
systemic circulation are of more interest. These 
experiments are few and all are focused on short term 
results, i.e. up to two months. Last but not least, there 
are no patient series in whom a tissue engineered 
valve is implanted. It is also obvious that implantation 
of glutaraldehyde fixed porcine valves or pericardial 
bovine valves cannot be considered as “tissue 
engineering”.  
There are still major questions which need to be 
solved. First, have the components of native valves 
and their interaction been identified? Although this 
information is necessary to construct TEHV in an 
adequate way, it might not be the case since it has 
been recently deemed to be necessary to compare 
human valves with porcine and ovine valves. This 
comparison should have been done long time ago! 
Second, do properties of in vitro constructs correlate 
with in vivo results such as durability, freedom of re-
operation and event free survival? Will living cells in 
these constructs behave in the desired way, if these 
have been used? Animal studies thus far were limited 
to a few months, while a valve in clinical practice needs 
to have a durability of more than 10 years. Moreover, it 
is by no means certain that an animal model represents 
clinical situations adequately. In ovine models, for 
example, fibrosis occurs much more extensively [34]. 
Third, is the behaviour of a living device such as TEHV 
predictable enough once it has been implanted? And if 
Table 2:  In Vivo Studies  
Reference Animal Procedure Scaffold Cells Analysis Follow-up 
25 porcine pulmonary decellularized none  IHC, TEM gene expr 6 & 15 months 
26 ovine  TPVI homologous none  hemodynamic 24 weeks  
27 ovine  TPVI stented valve art. EC/SMC bm-CD133+ IHC hemodynamic  
28 goat Ap-Ao autologous  none hemodynamic 2 months  
   connect. tissue none IHC  
29 rat infrarenal decellularized none IHC, MRI 8 weeks 
  aortic pulmon valve ovine vascular Doppler  
30 ovine TPVI intest submuc EC & MFB angiography, IHC 4 weeks 
31 rat Infrarenal aortic decell. Aortic valve isogenic EC & MFB Doppler, IHC 4 weeks  
32 ovine pulmonary decell pulmon valve autologous EPC CD133+ ab Biomechanical IHC 1 – 3 months 
33 ovine TPVI synthetic Autologous vascular & stem cells echo, angio IHC 8 weeks  
ab: antibodies; Ap-Ao: apico-aortic bypass; art: arterial; angio: angiography; coon: connective; decell: decellularized; bm-CD133+: bone marrow derived CD133 
pistive cells; EC; endothelial cells; EPC: endothelial progenitor cells; expr: expression; IHC: immunohistochemistry; intest submuc: intestinal submucosa; MFB: 
myofibroblasts; MSC: mesenchymal stem cells; SMC: smooth muscle cells; PTVI: transcatheter pulmonary valve implantation; pulmon: pulmonary; TEM: 
transmission electron microscope  
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not, can patient-related factors, which are responsible 
for the variation in behaviour be identified? Fourth, 
there is a universal bias caused by a tendency not to 
publish negative results. Much is to learn from failures, 
but such results have published been rarely. Since one 
cannot learn from what has not been published, the 
same futile efforts will be made over and over again. 
Fifth, there are non-scientific aspects. When a device 
contains living cells, regulation by FDA and CE marking 
become much more difficult. Commercialization can 
also be a major hurdle: one has to compete against 
established values such as pericardial valves which 
have a very predictable outcome in terms of survival 
and adverse events such as structural valve 
degeneration and thromboembolic events. Even if 
today, a perfectly working TEHV is produced, the proof 
of its long-term durability may require 10, 15 or even 20 
years. The limitations to produce a viable TEHV device 
can only be overcome if 1) all failed experiments are 
published, because one learns most from failure, 2) 
one source of cells for endothelial lining and possible 
another source for repopulation of the matrix itself can 
be found which is superior to all other cell sources, 3) 
one matrix can be identified which is superior to all 
other scaffolds in terms of durability, 4) long-term 
animal results can be produced and 5) agreement can 
be reached how precisely and by which criteria the 
devices can be evaluated in-vitro as well as in-vivo. 
Any tissue engineered device has to compete against 
established values such as the Carpentier-Edwards 
pericardial valve which as a durability of 15 years or 
more in most elderly patients. Contribution of 
manufacturers can only be obtained when a scientific 
and commercial viable solution can be demonstrated. 	  
CONCLUSIONS 
Tissue engineered have has been promising, but its 
fulfilment is not about to come in any time soon. Most 
experiments are in-vitro with an almost endless variety 
in scaffolds, cells and culturing conditions. In-vivo 
experiments are mostly limited to pulmonary positions, 
which has a lower pressure regimen than the systemic 
circulation. With exception of homograft devices and 
glutaraldehyde fixed xenografts, which cannot be called 
tissue engineered heart valves, there are no patient 
series. It will be difficult for any TEHV to compete with 
existing durable biological heart valves. There are 
some limitations in this work: only the last 5 years have 
been searched and the focus was directed on patients 
with aortic valve disease. However, experiences of the 
last 5 years can learn enough about the lack of 
progress that has been made. This work also excluded 
decellularized xenografts such as Contegra bovine 
jugular vein, Shelhigh, Synergraft and Matrix P / Matrix 
P plus devices. These are in use for reconstruction of 
the right ventricular outflow tract, in the correction of 
congenital heart defects. Moreover, one could argue if 
these really belong to the class of TEHV.  
CONFLICT OF INTERESTS AND ACKNOWLEGE- 
MENTS 
There are none to declare. 
FUNDING 
None 
REFERENCES 
[1] Stassano P, Di Tommaso L, Monaco M, et al. Aortic Valve 
Replacement A Prospective Randomized Evaluation of 
Mechanical Versus Biological Valves in Patients Ages 55 to 
70 Years. J Am Coll Cardiol 2009; 54: 1862-1868. 
http://dx.doi.org/10.1016/j.jacc.2009.07.032 
[2] Mistiaen W, Van Cauwelaert Ph, Muylaert Ph, Sys SU, 
Harrisson F, Bortier H. Thrombo-embolism after aortic valve 
replacement in elderly with a Carpentier-Edwards perimount 
TM bioprosthesis. J Thorac Cardiovasc Surg 2004; 127 (4): 
1166-1170 
http://dx.doi.org/10.1016/j.jtcvs.2003.11.010 
[3] Mistiaen W, Van Cauwelaert Ph, Muylaert Ph, Wuyts Fl, 
Harrisson F, Bortier H. Risk factors and survival after aortic 
valve replacement in octogenarians. J Heart Valve Dis 2004; 
13(4): 538-544. 
[4] Mistiaen W, Van Cauwelaert Ph, Muylaert Ph, Wuyts F, 
Bortier H. Risk factors for congestive heart failure after aortic 
valve replacement with a Carpentier-Edwards pericardial 
prosthesis in the elderly. J Heart Valve Dis 2005; 14: 774-9. 
[5] Melina G, De Robertis F, Gaer JA, Amrani M, Khaghani A, 
Yacoub MH. Mid-term pattern of survival, hemodynamic 
performance and rate of complications after Medtronic 
freestyle versus homograft full aortic root replacement: 
results from a prospective randomized trial. J Heart Valve Dis 
2004; 13: 972-975; discussion 975-976. 
[6] Schoen FJ. Heart valve tissue engineering. Quo Vadis? Curr 
Opin Biotechnol. 2011 
http://dx.doi.org/10.1016/j.copbio.2011.01.004 
[7] Masoumi N, Annabi N, Assmann A, et al. Tri-layered 
elastomeric scaffolds for engineering heart valve leaflets. 
Biomaterials 2014; 35(27): 7774-7785. 
http://dx.doi.org/10.1016/j.biomaterials.2014.04.039 
[8] Masoumi N, Larson BL, Annabi N, et al, Electrospun PGS: 
PCL Microfibers Align Human Valvular Interstitial Cells and 
Provide Tunable Scaffold Anisotropy Adv Healthcare Mater 
2014; 3(6): 929-939. 
[9] Dube J, Bourget JM, Gauvin R, et al. Progress in developing 
a living human tissue engineered tri-leaflet heart valve 
assembled from tissue produced by the self-assembly 
approach. Acta Biomateralia 2014; 10(8): 3563-3570. 
http://dx.doi.org/10.1016/j.actbio.2014.04.033 
[10] Wilczek P, Malota Z, Lesiak A, et al. Age-related changes in 
biomechanical properties of transgenic porcine pulmonary 
and aortic conduits. Biomedical Mat 2014; 9(5): Article 
Number: 055006; 
http://dx.doi.org/10.1088/1748-6041/9/5/055006 
 
10 International Journal of Cardiology and Lipidology Research, 2016, Vol. 3, No. 1 Wilhelm P. Mistiaen 
[11] Moreira R, Gesche V, Hurtado-Aguilar LG, et al. TexMi: 
Development of Tissue-Engineered Textile-Reinforced Mitral 
Valve Prosthesis. Tissue Engineering Part C-Methods 2014; 
20(9): 741-748. 
http://dx.doi.org/10.1089/ten.tec.2013.0426 
[12] Eslami M, Vrana NE, Zorlutana P, et al. Fiber-reinforced 
hydrogel scaffolds for heart tissue engineering. J Biomat 
Applic 2014; 29(3): 399-410. 
http://dx.doi.org/10.1177/0885328214530589 
[13] Alfonso A, Rath S, Rafiee P, et al. Glycosaminoglycan 
entrapment by fibrin in engineered heart valve tissues Acta 
Biomateralia 2013; 9(9): 8149-8157. 
[14] Sant S, Iyer D, Gaharwar AK, Patel A, Khademhosseine A. 
Effect of biodegradation and de novo matrix synthesis on the 
mechanical properties of valvular interstitial cell-seeded 
polyglycerol sebacate-polycaprolactone scaffolds Acta 
Biomateralia 2013; 9(4): 5963-5973. 
[15] Syedain ZH, Bradee AR, Kren S, Taylor DA, Tranquillo RT. 
Decellularized Tissue-Engineered Heart Valve Leaflets with 
Recellularization Potential. Tissue Engineering Part A 2013; 
19(5-6): 759-769. 
http://dx.doi.org/10.1089/ten.tea.2012.0365 
[16] Ferdous Z, Jo H, Nerem RM. Strain Magnitude-Dependent 
Calcific Marker Expression in Valvular and Vascular Cells. 
Cells Tissues Organs 2013; 197(5): 372-383. 
http://dx.doi.org/10.1159/000347007 
[17] Van Geemen D, Driessen-Mol A, Grootzwagers LGM, et al. 
Variation in tissue outcome of ovine and human engineered 
heart valve constructs: relevance for tissue engineering. 
Regenerative Med 2012; 7(1): 59-70. 
http://dx.doi.org/10.2217/rme.11.100 
[18] Weber B, Zeisberger SM, Hoerstrup SP. Prenatally 
harvested cells for cardiovascular tissue engineering: 
Fabrication of autologous implants prior to birth. Placenta 
2011; 32(suppl4): S316-S319. 
http://dx.doi.org/10.1016/j.placenta.2011.04.001 
[19] Kaminski A, Klopsch C, Mark P, et al. Autologous Valve 
Replacement-CD133(+) Stem Cell-Plus-Fibrin Composite-
Based Sprayed Cell Seeding for Intraoperative Heart Valve 
Tissue Engineering. Tissue Engin Part C-Methods 2011; 
17(3): 299-309. 
http://dx.doi.org/10.1089/ten.tec.2010.0051 
[20] Tedder ME, Simionescu A, Chen J, Liao J, Simionescu DT. 
Assembly and Testing of Stem Cell-Seeded Layered 
Collagen Constructs for Heart Valve Tissue Engineering. 
Tissue Engineering Part A 2011; 17(1-2): 25-36. 
http://dx.doi.org/10.1089/ten.tea.2010.0138 
[21] Luo J, Korossis SA, Wilshaw SP, et al. Development and 
Characterization of Acellular Porcine Pulmonary Valve 
Scaffolds for Tissue Engineering. Tissue Engineering PART 
A 2014; 20(21-22): 2963-2974. 
http://dx.doi.org/10.1089/ten.tea.2013.0573 
[22] Bayrak A, Tyralla M, Ladhoff J, et al. Human immune 
responses to porcine xenogeneic matrices and their 
extracellular matrix constituents in vitro. Biomaterials 2010; 
31(14): 3793-380. 
http://dx.doi.org/10.1016/j.biomaterials.2010.01.120 
[23] Martin C, Sun W. Biomechanical characterization of aortic 
valve tissue in humans and common animal models. J 
Biomed Mater Res Part A 2012; 100A(6): 1591-1599. 
http://dx.doi.org/10.1002/jbm.a.34099 
[24] Schleicher M, Sammler G, Schmauder M, et al. Simplified 
Pulse Reactor for Real-Time Long-Term In vitro Testing of 
Biological Heart Valves. Ann Biomed Engineering 2010; 
38(5): 1919-1927. 
http://dx.doi.org/10.1007/s10439-010-9975-8 
[25] Iop L, Bonetti A, Naso F, et al. Decellularized Allogeneic 
Heart Valves Demonstrate Self-Regeneration Potential after 
a Long-Term Preclinical Evaluation . PLOS ONE 2014; 9(6): 
Article Number: e99593 
http://dx.doi.org/10.1371/journal.pone.0099593 
[26] Driessen-Mol A, Emmert M, Dijkman PE, et al. Transcatheter 
Implantation of Homologous "Off-the-Shelf" Tissue 
Engineered Heart Valves With Self-Repair Capacity. J Am 
Coll Cardiol 2014; 63(13): 1320-1329. 
http://dx.doi.org/10.1016/j.jacc.2013.09.082 
[27] Boldt J, Lutter G, Pohanke J, et al. Percutaneous Tissue-
Engineered Pulmonary Valved Stent Implantation: 
Comparison of Bone Marrow-Derived CD133+-Cells and 
Cells Obtained from Carotid Artery. Tissue Engineering part 
C-Methods 2013; 19(5): 363-374. 
http://dx.doi.org/10.1089/ten.tec.2012.0078 
[28] Takewa Y, Yamanami M, Kishimoto Y, et al. In vivo 
evaluation of an in-body, tissue-engineered, completely 
autologous valved conduit (biovalve type VI) as an aortic 
valve in a goat model J Artif Organs (2013) 16: 176-184. 
http://dx.doi.org/10.1007/s10047-012-0679-8 
[29] Assmann A, Akhyari P, Delfs C, et al. Development of a 
Growing Rat Model for the In vivo Assessment of Engineered 
Aortic Conduits. J Surg Res 2012; 176(2): 367-375. 
http://dx.doi.org/10.1016/j.jss.2011.10.009 
[30] Metzner A, Stock UA, Iino K, et al. Percutaneous pulmonary 
valve replacement: autologous tissue-engineered valved 
stents. Cardiovasc Res 2010; 88(3): 453-461. 
http://dx.doi.org/10.1093/cvr/cvq212 
[31] Kallenbach K, Sorrentino S, Mertsching H, et al. A Novel 
Small-Animal Model for Accelerated Investigation of Tissue-
Engineered Aortic Valve Conduits. Tissue Engineering Part 
C-Methods 2010; 16(1): 41-50. 
http://dx.doi.org/10.1089/ten.tec.2008.0595 
[32] Jordan JE, Williams JK, Lee SJ, Raghavan D, Atala A, Yoo 
JJ. Bioengineered self-seeding heart valves. J Thorac 
Cardiovasc Surg 2012; 143(1): 201-208. 
http://dx.doi.org/10.1016/j.jtcvs.2011.10.005 
[33] Schmidt D, Dijkman PE, Driessen-Mol A, et al. Minimally-
Invasive Implantation of Living Tissue Engineered heart 
Valves A Comprehensive Approach From Autologous 
Vascular Cells to Stem Cells. J Am Coll Cardiol 2010; 56(6): 
510-520 
http://dx.doi.org/10.1016/j.jacc.2010.04.024 
[34] Schoen FJ. Pathologic findings in explanted clinical 
bioprosthetic valves fabricated from photo-oxidized bovine 
pericardium. J Heart Valve Dis 1998; 7: 174-179. 
 
Received on 25-01-2016 Accepted on 22-02-2016 Published on 11-03-2016 
 
http://dx.doi.org/10.15379/2410-2822.2016.03.01.02 
© 2016 Wilhelm P. Mistiaen; Licensee Cosmos Scholars Publishing House. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, 
provided the work is properly cited.  
 
